Polyarticular Juvenile Idiopathic Arthritis Clinical Trial
Official title:
Post-Marketing Surveillance of Humira Injection in Korean JIA Patients Under the New-Drug Re-examination
Approximately 600 pediatric patients prescribed Humira Injection in usual practice according to the approved Korean product label will be registered into this observational study. Baseline data will be obtained at enrollment including demographics, underlying diseases and complications especially in regard to purified protein derivative (PPD) skin test, chest X-ray. At routine visits for Humira Injection administration which will occur according to usual medical practice, concomitant medication information and adverse events information will be collected for up to 70 days after the last administration of Humira.
n/a
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05411211 -
An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA)
|
||
| Completed |
NCT04018599 -
Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
|
Phase 1 | |
| Completed |
NCT00144625 -
Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
|
Phase 3 | |
| Active, not recruiting |
NCT05754710 -
Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis
|